Pseudomonas Aeruginosa Treatment Market: Rising Hospital-Acquired Infection and Surgical Site Infections Caused due to Pseudomonas Aeruginosa are Projected to Boost Market Growth at a Healthy CAGR of 8.10% During the Forecast Period of 2023 to 2032

Pune, India, October 2022/MRFR Press Release/- Market Research Future has published its Half-Cooked Research Report on the Global Pseudomonas Aeruginosa Treatment Market.

Market Highlights

According to MRFR analysis, Pseudomonas Aeruginosa Treatment Market is expected to register a CAGR of 8.10% during the forecast period of 2023 to 2032 and is likely to be valued at USD 9.8 Billion by 2032.

Pseudomonas Aeruginosa is a soil bacterium that causes diseases in a plant, animal and humans. It has an antibiotic resistance property because of which it creates life-threatening conditions that are difficult to treat. Pseudomonas Aeruginosa is one of the key reasons for having surgical site infection and hospital-acquired infection in patient hospitalized for a longer period. It is estimated that around 1.7 million patient suffers from hospital acquire infection and 99,000 dies each year from the same.

The growth of the global Pseudomonas Aeruginosa treatment market is determined by numerous factors such as an increasing number of surgeries, a growing geriatric population, increasing cases of hospital-acquired infection, which is directly responsible for increasing global Pseudomonas Aeruginosa treatment market. However, the side effects associated with the medication and lack of awareness about the disease caused due to Pseudomonas Aeruginosa are likely to hamper the growth of the global Pseudomonas Aeruginosa treatment market during the forecast period.

Several market players currently dominate the global Pseudomonas Aeruginosa treatment market. The key players are involved in product launches and strategic collaborations to strengthen their market positions.

Segmentation

The Global Pseudomonas Aeruginosa Treatment Market has been segmented based on medication, route of administration, and distribution channel.

The market, based on medication, has been divided into monotherapy and combination therapy. Combination therapy is likely to hold the maximum market share in the global Pseudomonas Aeruginosa treatment market.

The global Pseudomonas Aeruginosa treatment market on the basis of route of administration has been segregated into nasal, oral, and intravenous. The oral segment is expected to hold a larger share of the market share owing to the rising demand for the drugs.

The distribution channel segment of the market consists of hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment is expected to hold the largest share of the market as there are a repetitive purchase of medicines from these locations.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Pseudomonas Aeruginosa Treatment Market Research Report

Key Players

Some of the key players in the Global Pseudomonas Aeruginosa Treatment Market are Pfizer, Inc. (UK), Gilead Sciences Inc (US), Lupin Pharmaceuticals, Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), Novartis AG (Switzerland), PARI Medical Holding GmbHb (Germany), AstraZeneca (UK), Humanigen Inc (US), Merck & Co., Inc. (US), AmpliPhi Biosciences Corp (US), Bristol-Myers Squibb Co.(US), Aradigm Corp (US), Allergan Plc (Ireland), Janssen Pharmaceuticals, Inc.(Belgium), and Bayer AG (Germany).

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

Americas has been segmented into North America and Latin America, with the North American market being divided into the US and Canada. The Americas is projected to hold the largest market share owing to the increasing number of surgical sites infection and increasing demand for antibiotics to treat the same drives the market growth during the forecasted period.  

The European Pseudomonas Aeruginosa treatment market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Pseudomonas Aeruginosa treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the rising geriatric population and the presence of a large patient pool, the market in Asia-Pacific is expected to be the fastest-growing. The Pseudomonas Aeruginosa Treatment market in the Middle East & Africa has been divided into the Middle East and Africa.